Business
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer.\n\n \n \n \n \n \n \n\n \n\"Dr. Su is a physicianâscientist and pharmaceutical industry leader who brings tremendous experience guiding products through discovery, clinical development, approval, and global commercialization,\" said Richard Paulson, MBA, Chief Executive Officer of Karyopharm. \"His expertise and counsel will be critical to us as we expand into different patient populations and potential new indications in oncology. We are delighted to welcome him to our team and look forward to the insight he will provide as part of our Board of Directors.\"\n\"I am pleased to join the Board of Karyopharm at this exciting time in the company's next phase of growth,\" said Dr. Su. \"I look forward to actively engaging with my fellow Board members and the Karyopharm leadership team to advance its core programs and deliver for patients in need of new cancer treatment options.\"\n\"Dr. Su is a passionate leader focused on delivering medicines through all phases of the clinical development lifecycle,\" said Barry Greene, Lead Independent Director of the Karyopharm Board. \"We are thrilled to welcome such a strong strategic advisor and industry leader to our Board of Directors.\"\nPrior to joining Marengo, Dr. Su served as SVP, Global Head of Oncology Business Franchise, including US Head of the Oncology Business Unit, at Merck KGaA. Prior to that, he served as Chief Medical Officer at EMD Serono and headed leadership functions at Sanofi's Oncology Division and GlaxoSmithKline. Before his industry career, Dr. Su served on the faculty of Duke University Medical School where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then at the University of Florida where he was the director of the Cell and Gene Therapy program. He received his Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Tor...